Open access
Open access
Powered by Google Translator Translator

RCT: Sintilimab vs. placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma.

20 Apr, 2022 | 09:28h | UTC

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial – The BMJ

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.